Gelhorn, Heather L.
Eremenco, Sonya
Skalicky, Anne M.
Balantac, Zaneta
Cimms, Tricia
Halling, Katarina
Sexton, Chris
Funding for this research was provided by:
AstraZeneca
Article History
Received: 16 May 2017
Accepted: 5 October 2017
First Online: 27 March 2018
Ethics approval and consent to participate
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by MD Anderson 2013–0913; Roswll Park Cancer Institute 239,113; Scott & White 130,030; Moffitt Cancer Center 17,444.
: Not applicable.
: Dr. Halling is currently employed and Ms. Cimms formerly employed by AstraZeneca. Dr. Gelhorn, Ms. Skalicky, and Ms. Balantac are current salaried employees and Dr. Sexton and Ms. Eremenco are former employees of Evidera, a consulting company, which has received funding from AZ for conducting the study. They are precluded from receiving payment/honoraria directly from companies for which Evidera consults. The authors have no other relevant affiliations or financial involvement with any organization or entity with financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.